HAEM5:In situ mantle cell neoplasm - Revision history

Bailey.Glen at 17:17, 3 July 2025

2025-07-03T17:17:25Z

@@ Line 33: / Line 33: @@
 |In situ mantle cell neoplasm
 |}
 ==Related Terminology==

Bailey.Glen at 21:36, 25 May 2025

2025-05-25T21:36:51Z

← Older revision		Revision as of 16:36, 25 May 2025
Line 141:		Line 141:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 244:		Line 244:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 277:		Line 277:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 325:		Line 325:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:13, 25 May 2025

2025-05-25T20:13:10Z

← Older revision		Revision as of 15:13, 25 May 2025
Line 48:		Line 48:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|In situ mantle cell neoplasia
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|In situ mantle cell lymphoma; mantle cell lymphoma–like B cells of uncertain/undetermined significance
	\|}		\|}

Bailey.Glen at 17:37, 24 March 2025

2025-03-24T17:37:58Z

← Older revision		Revision as of 12:37, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:In situ mantle cell neoplasm}}		{{DISPLAYTITLE:In situ mantle cell neoplasm}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Rina Kansal, MD; Versiti Blood Center of Wisconsin		Rina Kansal, MD; Versiti Blood Center of Wisconsin

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Jennelleh at 16:32, 8 March 2025

2025-03-08T16:32:08Z

Show changes

Jennelleh at 16:22, 8 March 2025

2025-03-08T16:22:56Z

Show changes

Jennelleh at 16:17, 8 March 2025

2025-03-08T16:17:31Z

@@ Line 1: / Line 1: @@
 {{DISPLAYTITLE:In situ mantle cell neoplasm}}
 [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
 {{Under Construction}}
-<blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:In Situ Mantle Cell Neoplasia]].
+<blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:In Situ Mantle Cell Neoplasia]].
 }}</blockquote>
@@ Line 753: / Line 754: @@
 ==Additional Information==
-Put your text here
+This disease is <u>defined/characterized</u> as detailed below:
 ==Links==
@@ Line 774: / Line 805: @@
 <nowiki>*</nowiki>''Citation of this Page'': “In situ mantle cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_mantle_cell_neoplasm</nowiki>.
-[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases I]]
+[[Category:HAEM5]]

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-13T22:36:28Z

Gene Mutations (SNV/INDEL)

@@ Line 629: / Line 629: @@
 |}
 ==Gene Mutations (SNV/INDEL)==
 There are numerous publications for gene mutations in overt mantle cell lymphoma. A recent systematic meta-analysis of 32 studies published during 2006 to 2019, excluding review articles, detailed the findings for gene mutations in mantle cell lymphoma by analyzing 2127 individual overt mantle cell lymphoma patients and 2173 samples that were included in the analyzed studies.<ref name=":10">{{Cite journal|last=Hill|first=Holly A.|last2=Qi|first2=Xinyue|last3=Jain|first3=Preetesh|last4=Nomie|first4=Krystle|last5=Wang|first5=Yucai|last6=Zhou|first6=Shouhao|last7=Wang|first7=Michael L.|date=2020-07-14|title=Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis|url=https://pubmed.ncbi.nlm.nih.gov/32598477|journal=Blood Advances|volume=4|issue=13|pages=2927–2938|doi=10.1182/bloodadvances.2019001350|issn=2473-9537|pmc=7362354|pmid=32598477}}</ref>  These studies included the nodal and the leukemic forms of overt mantle cell lymphoma. As per this meta-analysis, in overt mantle cell lymphoma tumor or bone marrow samples at diagnosis or baseline, the most frequent genetic abnormalities occurred in the ''ATM'' (43.5%), ''TP53'' (26.8%), ''CDKN2A'' (23.9%), ''CCND1'' (20.2%), ''NSD2'' (15.0%), ''KMT2A'' (8.9%), ''S1PR1'' (8.6%), and ''CARD11'' (8.5%) genes.<ref name=":10" /> Aberrations in ''IGH'' (38.4%) and ''MYC'' (20.8%) were detected primarily through cytogenetic methods, also in those same tumor specimens.<ref name=":10" />

Bailey.Glen: /* Individual Region Genomic Gain/Loss/LOH */

2025-02-13T22:35:58Z

Individual Region Genomic Gain/Loss/LOH

@@ Line 493: / Line 493: @@
 ==Individual Region Genomic Gain/Loss/LOH==
 These have not been studied specifically for in situ mantle cell neoplasm.
@@ Line 538: / Line 590: @@
 Common recurrent secondary finding for t(8;21) (add reference).
 |}
 ==Characteristic Chromosomal or Other Global Mutational Patterns==

Bailey.Glen: /* Gene Rearrangements */

2025-02-13T22:35:30Z

Gene Rearrangements

@@ Line 414: / Line 414: @@
 ==Gene Rearrangements==
 The balanced translocation t(11;14)(q13;q32) is characteristic of mantle cell lymphoma and was identified in all cases of histologically identified in situ mantle cell neoplasm (whenever it was examined for in addition to the overexpression of cyclin D1 protein).
@@ Line 431: / Line 490: @@
 |Not yet known, if any
 |The t(11;14) is characteristic of in situ mantle cell neoplasm and overt mantle cell lymphoma in the appropriate morphology and clinical context. However, this translocation may also be present in other lymphoid neoplasms and has also been identified in healthy individuals at a lower incidence than the t(14;18) translocation in healthy individuals.<ref>{{Cite journal|last=Hirt|first=Carsten|last2=Schüler|first2=Frank|last3=Dölken|first3=Lars|last4=Schmidt|first4=Christian A.|last5=Dölken|first5=Gottfried|date=2004-08-01|title=Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR|url=https://pubmed.ncbi.nlm.nih.gov/15265798|journal=Blood|volume=104|issue=3|pages=904–905|doi=10.1182/blood-2004-02-0738|issn=0006-4971|pmid=15265798}}</ref><ref>{{Cite journal|last=Nambiar|first=Mridula|last2=Raghavan|first2=Sathees C.|date=2010-01|title=Prevalence and analysis of t(14;18) and t(11;14) chromosomal translocations in healthy Indian population|url=https://pubmed.ncbi.nlm.nih.gov/19488754|journal=Annals of Hematology|volume=89|issue=1|pages=35–43|doi=10.1007/s00277-009-0755-1|issn=1432-0584|pmid=19488754}}</ref><ref>{{Cite journal|last=Lecluse|first=Y.|last2=Lebailly|first2=P.|last3=Roulland|first3=S.|last4=Gac|first4=A.-C.|last5=Nadel|first5=B.|last6=Gauduchon|first6=P.|date=2009-06|title=t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals|url=https://pubmed.ncbi.nlm.nih.gov/19242498|journal=Leukemia|volume=23|issue=6|pages=1190–1193|doi=10.1038/leu.2009.31|issn=1476-5551|pmid=19242498}}</ref>
 |}
 ==Individual Region Genomic Gain/Loss/LOH==